The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation
a Prospective, Multi-center, Open-label, Non-inferiority, Randomized, Controlled Registration Trial of the Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation
MicroPort NeuroTech Co., Ltd.
116 participants
May 28, 2024
INTERVENTIONAL
Conditions
Summary
This study is designed as a prospective, multi-center, open-label, non-inferiority, randomized controlled clinical trial. The control device is Onyx Liquid Embolic System marketed by Micro Therapeutics Inc. DBA ev3 Neurovascular (NMPA (J) 20173136690). According to the inclusion and exclusion criteria specified in this trial protocol, approximately 116 subjects with brain arteriovenous malformation will be enrolled for interventional embolization treatment. The subjects will undergo follow-up before the surgery, after device implantation, at discharge, 1 month (± 7 days), 6 months (± 30 days), and 12 months (± 60 days) after the first embolization. When necessary, unscheduled follow-up will be conducted to record various indicators for evaluating the safety and effectiveness of liquid embolic agents in the treatment of brain arteriovenous malformations.
Eligibility
Inclusion Criteria5
- Age ≥ 18 and ≤ 80 years at the time of signing the informed consent
- Subjects with brain arteriovenous malformation diagnosed by CT/MRI/DSA
- The target brain arteriovenous malformation is classified by Spetzler-Martin in the range of Ⅰ \~ Ⅳ
- Subjects themselves and/or their guardian are able to understand the purpose of the study, consent to participate, and sign the informed consent form
- Brain arteriovenous malformations deemed suitable for liquid embolic agent intervention as assessed by the investigator
Exclusion Criteria12
- Multiple brain arteriovenous malformations
- Brain arteriovenous malformation complicated with blood flow-related aneurysm that may require staged and delayed treatment using other methods within the one-year follow-up period
- Brain arteriovenous malformation with a history of stereotactic radiosurgery within 3 years
- Brain arteriovenous malformation with bleeding within 1 week
- Brain arteriovenous malformation with an expected number of embolizations ≥ 4
- Brain arteriovenous malformation scheduled for surgical resection after embolization
- mRS score ≥ 3
- Subjects unsuitable for anesthesia or endovascular surgical treatment, due to major diseases of cardio, lung, liver, spleen or kidney, malignant brain tumors, severe active infection, disseminated intravascular coagulation, or a history of severe mental illness, etc
- Subjects who undergo major surgical procedures (such as tumor resection, vital organ surgery, etc.) within 30 days prior to signing the informed consent form, or those scheduled for such procedures within 60 days after signing the informed consent form
- Contraindications for liquid embolic agent treatment, including but not limited to: contraindications for DSA, severe allergy or intolerance to contrast agents, severe allergy or intolerance to antiplatelet or anticoagulant medications required for treatment, or severe allergy to tantalum metal
- Pregnant or lactating women
- Subjects participating in other drug or device studies that have not reached their endpoints or who have just withdrawn from the group for less than one month
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
liquid embolic agent
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07314047